Abstract

Ihab Barsoum Fahim, Saeed Abd Elbaky Gad, Mahmoud Ezat Hegazy, Mahmoud Ahmed Sharafeddin.

Background: the most common cause of death in HIV/HCV-co infected patients’ liver-related mortality. So, treatment of HCV infection in co infected individuals is considered a priority.
Objectives: to evaluate the safety and efficacy of DAAs (sofosbuvir & daclatasvir) in treating chronic HCV in HCV-HIV co-infected Egyptian patients.
Patients and methods: The study includes 18 HCVHIV co-infected patients (14 males 77.8 % and 4 females 22.8 %). Their standard age +/- 32.89 years, 61% of them are smokers and IV addicts. Patients divided according to HIV PCR into 2 groups; Group I including 12 Patients with HIV PCR > 50 copiesmm and Group II including 6 patients with HIV PCR < 50 copies mm.
Results: The rates of a sustained virologic response (SVR) at post-treatment week 12 (SVR 12) were high (17/18, 94.4%). There was a high safety profile on using sofosbuvir & daclatasvir and no patient discontinued treatment because of adverse events. Also, AST & ALT were significantly decreased at end of treatment and 12 weeks after treatment, CD4 count was significantly increased. Otherwise there are no significant changes in both hematological and chemistry labs.
Conclusions: Daclatasvir plus sofosbuvir for 12 weeks resulted in a high rate of sustained virologic response in patients co infected with HIV and HCV with high safety profile after treatment completion